Royal Bank of Canada Reiterates Outperform Rating for Pyxis Oncology (NASDAQ:PYXS)

Pyxis Oncology (NASDAQ:PYXS)‘s stock had its “outperform” rating restated by investment analysts at Royal Bank of Canada in a research note issued on Thursday, Benzinga reports. They currently have a $7.00 target price on the stock. Royal Bank of Canada’s price target would suggest a potential upside of 89.70% from the stock’s current price.

PYXS has been the topic of several other research reports. Stifel Nicolaus began coverage on shares of Pyxis Oncology in a research note on Thursday, August 8th. They set a “buy” rating and a $10.00 price objective on the stock. HC Wainwright reissued a “buy” rating and set a $7.00 price target on shares of Pyxis Oncology in a research report on Friday, August 16th. Eight equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat, Pyxis Oncology currently has a consensus rating of “Buy” and a consensus price target of $9.00.

Pyxis Oncology Stock Up 0.3 %

NASDAQ:PYXS opened at $3.69 on Thursday. Pyxis Oncology has a 12-month low of $1.35 and a 12-month high of $6.85. The stock’s fifty day simple moving average is $3.59 and its 200-day simple moving average is $4.01. The firm has a market capitalization of $217.30 million, a P/E ratio of -2.71 and a beta of 1.28.

Pyxis Oncology (NASDAQ:PYXS) last released its earnings results on Wednesday, August 14th. The company reported ($0.29) earnings per share for the quarter, beating the consensus estimate of ($0.33) by $0.04. As a group, equities research analysts expect that Pyxis Oncology will post -1.07 earnings per share for the current year.

Institutional Investors Weigh In On Pyxis Oncology

Large investors have recently made changes to their positions in the stock. Vestal Point Capital LP bought a new stake in Pyxis Oncology in the 4th quarter valued at $792,000. Susquehanna Fundamental Investments LLC bought a new stake in shares of Pyxis Oncology in the first quarter valued at about $351,000. Cable Car Capital LLC acquired a new position in shares of Pyxis Oncology during the fourth quarter worth about $111,000. Decheng Capital LLC bought a new position in shares of Pyxis Oncology during the fourth quarter worth about $588,000. Finally, SG Americas Securities LLC acquired a new stake in Pyxis Oncology in the 1st quarter valued at approximately $59,000. Institutional investors own 39.09% of the company’s stock.

Pyxis Oncology Company Profile

Pyxis Oncology, Inc, a clinical stage company, engages in the development of therapeutics to treat cancers. Its lead antibody-drug conjugates (ADC) product candidate is PYX-201, an investigational novel ADC consisting of human immunoglobulin G1 (IgG1), which is in Phase 1 clinical trial to treat patients with relapsed or refractory solid tumors; and lead immuno-oncology (IO) product candidate is PYX-106, an investigational fully human IgG1 Siglec-15-targeting antibody that is in Phase 1 clinical trial to treat patients with advanced solid tumors.